Literature DB >> 12297934

Systemic immune response after laparoscopic and open cholecystectomy.

Shyr-Ming Sheen-Chen1, Han-Shiang Chen, Hock-Liew Eng, Wei-Jen Chen, Bruno Jawan.   

Abstract

The laparoscopic approach is thought to reduce the postoperative immunologic and metabolic effects of an open operation. This study was designed with the aim of comparing the systemic immune response after laparoscopic and open cholecystectomy. Seventeen patients with gallbladder stones were assigned to undergo either a laparoscopic (n = 9) or open (n = 8) approach. The postoperative immune response was assessed by measuring the serum levels of soluble Fas (sFas), soluble L-selectin (sL-selectin), and transforming growth factor-beta1 (TGFbeta1) preoperatively and 2 hours, 1 day, and 2 days postoperatively. Both approaches resulted in a significant decrease in sFas levels 1 and 2 days postoperatively. The open approach evoked a transient increase in sL-selectin levels 2 hours postoperatively. Moreover, the open approach resulted in a persistent, significant increase in TGFbeta1 levels postoperatively. Comparison of open versus laparoscopic cholecystectomy has shown no significant difference in sFas level and a statistically significant increase of sL-selectin (within 2 hours) and TGFbeta levels after open surgery. Although both laparoscopic and open cholecystectomy evoked an alteration of the systemic immune response, our data showed that such immune response may be less after the laparoscopic approach.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12297934     DOI: 10.1007/s00268-002-6388-3

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  24 in total

1.  A prospective randomized study of the systemic immune response after laparoscopic and conventional Nissen fundoplication.

Authors:  C Sietses; M J Wiezer; Q A Eijsbouts; R H Beelen; P A van Leeuwen; B M von Blomberg; S Meijer; M A Cuesta
Journal:  Surgery       Date:  1999-07       Impact factor: 3.982

Review 2.  Selectins: interpreters of cell-specific carbohydrate information during inflammation.

Authors:  L A Lasky
Journal:  Science       Date:  1992-11-06       Impact factor: 47.728

Review 3.  Laparoscopic surgery and the systemic immune response.

Authors:  F J Vittimberga; D P Foley; W C Meyers; M P Callery
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

4.  Distinct mechanisms of immunosuppression as a consequence of major surgery.

Authors:  T Hensler; H Hecker; K Heeg; C D Heidecke; H Bartels; W Barthlen; H Wagner; J R Siewert; B Holzmann
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

5.  Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta.

Authors:  C M Overall; J L Wrana; J Sodek
Journal:  J Biol Chem       Date:  1989-01-25       Impact factor: 5.157

6.  Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy.

Authors:  G P Midis; Y Shen; L B Owen-Schaub
Journal:  Cancer Res       Date:  1996-09-01       Impact factor: 12.701

7.  An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro.

Authors:  G Papoff; I Cascino; A Eramo; G Starace; D H Lynch; G Ruberti
Journal:  J Immunol       Date:  1996-06-15       Impact factor: 5.422

8.  Resistance to Fas-mediated apoptosis in human hepatoma cells.

Authors:  G Natoli; A Ianni; A Costanzo; G De Petrillo; I Ilari; P Chirillo; C Balsano; M Levrero
Journal:  Oncogene       Date:  1995-09-21       Impact factor: 9.867

9.  Soluble L-selectin is present in human plasma at high levels and retains functional activity.

Authors:  B Schleiffenbaum; O Spertini; T F Tedder
Journal:  J Cell Biol       Date:  1992-10       Impact factor: 10.539

10.  Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta.

Authors:  A E Postlethwaite; J Keski-Oja; H L Moses; A H Kang
Journal:  J Exp Med       Date:  1987-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.